drug
clesrovimab
Marketedupdated 6mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying clesrovimab
- phase3Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
- phase3Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
- phase2Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
News(2)
- Merck outlines 2027 as ‘another year of investment’ despite recent clinical winsEven as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial expansions over near-term margin growth, hoping to strengthen its long-term…fiercebiotech · 19d ago
- Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missThe anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…biospace · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that